- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Pfizer Ratings Report.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
The Trump administration's executive order on tax regulations could revive the defunct Allergan-Pfizer merger.
Corporate America shelled out big bucks for President Trump's inauguration.